Stock Detail
TRIMERIS INC
Biotechnology
TRMS @ Yahoo Finance | TRMS Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $3.07 | $16.06 | $-0.20 | -1.23% | 0.00 | $16.25 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $16.05 | $3.07 | 21,900 | 68.77M | 21,040 | 33.66 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 20.39 | 11.73 | 7.40 | -1.26 | -5.59 |
Stock Profile
Trimeris, Inc. engages in the identification, development, and commercialization of therapeutic agents that block viral infection by inhibiting viral fusion with host cells. Its principal drug candidate, Fuzeon, is a human immunodeficiency virus (HIV) fusion inhibitor approved in the United States, Canada, European Union, and other countries for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The company has a collaboration agreement with F. Hoffmann-La Roche, Ltd. to develop and market Fuzeon and T-1249, a replacement compound. Trimeris was founded by Dani Bolognesi and Tom Matthews in 1993 and is based in Morrisville, North Carolina.